Research programme: senolytic therapeutics - Centre for Drug Design and Discovery
Latest Information Update: 04 Oct 2022
At a glance
- Originator Centre for Drug Design and Discovery
- Class Antifibrotics; Antineoplastics; Senotherapeutics; Small molecules
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer; Pulmonary fibrosis; Renal fibrosis
Most Recent Events
- 28 Sep 2022 Research programme: senolytic therapeutics - Centre for Drug Design and Discovery is available for licensing as of 21 Sep 2022. https://www.cd3.be/collaboration
- 21 Sep 2022 Early research in Cancer in Belgium (unspecified route) (Centre for Drug Design and Discovery website, September 2022)
- 21 Sep 2022 Early research in Pulmonary fibrosis in Belgium (unspecified route) (Centre for Drug Design and Discovery website, September 2022)